DexCom, Inc. (DXCM) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is...
DexCom, Inc.'s revenue increased 15.6% year over year, from $4.03B to $4.66B.
Net income increased 45.1% over the same period, from $576.2M to $836.3M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 713% in total.
Operating cash flow grew 45.6% to $1.44B.
DexCom, Inc. maintains a healthy net profit margin of 17.9%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $2.59B+60.5% | $285.2M | $1.63B | $380.8M | $614.9M | $6.60B | N/A | $2.27B |
| Q1 FY2024 | $921.0M-64.4% | $146.4M | $561.9M | $101.1M | $209.2M | $6.48B | N/A | $2.25B |
| Q2 FY2024 | $1.93B+109.0% | $289.9M | $1.19B | $259.1M | $488.6M | $6.80B | N/A | $2.43B |
| Q3 FY2024 | $2.92B+51.6% | $424.5M | $1.78B | $411.1M | $688.1M | $6.35B | N/A | $1.98B |
| Q1 FY2025 | $1.04B-64.5% | $105.4M | $589.0M | $133.7M | $183.8M | $6.75B | N/A | $2.27B |
| Q2 FY2025 | $2.19B+111.7% | $285.2M | $1.28B | $346.3M | $486.8M | $7.33B | N/A | $2.57B |
| Q3 FY2025 | $3.40B+55.1% | $569.0M | $2.01B | $588.8M | $1.15B | $7.50B | N/A | $2.73B |
| Q1 FY2026 | $1.19B-65.0% | $199.5M | $750.3M | $255.3M | $525.6M | $6.63B | N/A | $2.96B |
Balance Sheet Summary (Latest Period)
Total Assets
$6.34B
Total Liabilities
$3.59B
Total Equity
$2.75B
Cash & Equivalents
$917.7M
Total Debt
N/A
Current Assets
$4.03B
Current Liabilities
$2.14B
Retained Earnings
$2.43B